Foot and Ankle / Plantar Fasciitis / PRP / VAS+FFI

This Circle helps physicians capture and monetize real-world data from their everyday delivery of PRP for Plantar Fasciitis.  

The Platelet Rich Plasma “PRP” Market is valued at 828.8 Billion in 2023, and is estimated to grow to over 3 Trillion by 2032. The prevalence of Plantar Fasciitis is around 10% of the population, with peak incidence in people aged 40 to 60. Plantar Fasciitis of adult men and women is treated area for PRP therapy. Manufacturers will thus increasingly spend on obtaining and maintaining regulatory approvals for marketing those products for Plantar Fasciitis. Increasingly, that spending will be focused on licensing real-world safety and efficacy data from their everyday customers.

This Circle helps physicians obtain and aggregate those high quality real-world data those companies are looking for. Participation is minimally burdensome, and members will receive recurring license fees once obtained and in accordance with their contribution of Plantar Fasciitis cases, outcomes and other case data.